Please use this identifier to cite or link to this item:
Title: Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Austin Authors: Nowak, Anna K;Lesterhuis, W Joost;Kok, Peey-Sei;Brown, Chris;Hughes, Brett Gm;Karikios, Deme J;John, Thomas ;Kao, Steven C-H;Leslie, Connull;Cook, Alistair M;Pavlakis, Nick;Briscoe, Karen;O'Byrne, Kenneth J;Karapetis, Christos S;Lam, Wei-Sen;Langford, Ailsa;Yip, Sonia;Stockler, Martin R
Affiliation: School of Biomedical Sciences, University of Western Australia, Perth, WA, Australia
Medical School, University of Western Australia, Perth, WA, Australia
National Centre for Asbestos Related Diseases, Perth, WA, Australia
Department of Medical Oncology, Fiona Stanley Hospital and Western Australia Country Health Service, Perth, WA, Australia
Flinders Medical Centre and Flinders University, Bedford Park, SA, Australia
Princess Alexandra Hospital and Queensland University of Technology, Brisbane, QLD, Australia
Mid North Coast Cancer Institute, Coffs Harbour Health Campus, Coffs Harbour, NSW, Australia
Royal North Shore Hospital and Northern Cancer Institute, Sydney, NSW, Australia
National Health and Medical Research Council, Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia
Sir Charles Gairdner Hospital, Nedlands, WA, Australia
Medical School, University of Western Australia, Perth, WA, Australia
University of Queensland, Brisbane, QLD, Australia
The Prince Charles Hospital and University of Queensland, Brisbane, QLD, Australia
Nepean Hospital, Kingswood, NSW, Australia
PathWest Laboratory Medicine, Nedlands, WA, Australia
Chris O'Brien Lifehouse, Camperdown, NSW, Australia
Olivia Newton-John Cancer Research Institute
Austin Health
Issue Date: Sep-2020 2020-09
Publication information: The Lancet. Oncology 2020; 21(9): 1213-1223
Abstract: There is a strong unmet need to improve systemic therapy in mesothelioma. Chemotherapy with cisplatin and pemetrexed improves survival in malignant pleural mesothelioma, and immune checkpoint inhibitors are an emerging treatment in this disease. We aimed to evaluate the activity of durvalumab, an anti-PD-L1 antibody, given during and after first-line chemotherapy with cisplatin and pemetrexed in patients with advanced malignant pleural mesothelioma. DREAM was a multicentre, single-arm, open-label, phase 2 trial done in nine hospitals in Australia. Eligible patients were aged 18 years or older and had histologically confirmed malignant pleural mesothelioma considered unsuitable for cancer-directed surgery, an Eastern Cooperative Oncology Group performance status of 0 or 1, and measurable disease as per the modified Response Evaluation Criteria in Solid Tumors version 1.0 (mRECIST) for mesothelioma that was previously untreated with systemic therapy. All histological subtypes were eligible. The first six participants were treated for two cycles in a safety run-in. All participants received cisplatin 75 mg/m2, pemetrexed 500 mg/m2, and durvalumab 1125 mg intravenously on day 1 of a 3-weekly schedule for a maximum of six cycles. Change from cisplatin to carboplatin with an area under the curve of 5 was permitted. Durvalumab was continued for a maximum of 12 months. The primary endpoint was progression-free survival at 6 months, measured according to mRECIST for malignant pleural mesothelioma and analysed in the intention-to-treat population. Safety analyses included all participants who receive at least one dose of any study drug. This study is registered with the Australia New Zealand Clinical Trials Registry, ACTRN12616001170415. Between Dec 28, 2016, and Sept 27, 2017, 55 participants were enrolled. 54 patients were eligible and were followed up for a median of 28·2 months (IQR 26·5-30·2). 31 (57%; 95% CI 44-70) of 54 patients were alive and progression-free at 6 months. The most common grade 3-4 adverse events were neutropenia (seven [13%] patients), nausea (six [11%]), and anaemia (four [7%]). A total of 60 serious adverse events occurred in 29 participants, five of which were considered possibly related to durvalumab. Five patients died during the study treatment; none of these five deaths were attributed to study treatment. The combination of durvalumab, cisplatin, and pemetrexed has promising activity and an acceptable safety profile that warrants further investigation in a randomised phase 3 trial. AstraZeneca.
DOI: 10.1016/S1470-2045(20)30462-9
Journal: The Lancet. Oncology
PubMed URL: 32888453
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Jun 9, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.